Table 1 STOPGAP trial key inclusion and exclusion criteria

Patients (age ≥ 18 -75 years) must have treatment naïve histologically or cytologically confirmed gastric or gastroesophageal adenocarcinoma and have received 3–4 months of first line systemic treatment without visceral metastatic progression

Any evidence of extensive retroperitoneal lymph node metastases not amenable to resection during gastrectomy

Must have peritoneal cytology positive disease or peritoneal carcinomatosis detected by imaging, laparoscopy, or laparotomy

Any evidence of small or large bowel obstruction except for gastric outlet obstruction due to primary malignancy

Performance status: ECOG performance status ≤ 2. ECOG 2 allowed if attributed to malignancy (rather than comorbidities)

History of another primary cancer within the last 3 years except for non-melanoma skin cancer, early-stage prostate cancer, or curatively treated cervical carcinoma in-situ and not treated with systemic therapy

Life expectancy of greater than 6 months

Prior surgery that would preclude safe diagnostic laparoscopy and port placement

Adequate organ and marrow function